Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells

被引：9

作者：

Gao, Chunzi ^{[1
]}

Wu, Xianzhen ^{[1
,2
]}

Yan, Ying ^{[1
,3
]}

Meng, Lingnan ^{[1
]}

Shan, Dan ^{[1
]}

Li, Ying ^{[1
]}

Han, Bo ^{[1
]}

机构：

[1] Harbin Med Univ, Affiliated Hosp 1, Dept Oncol, Ward 2, Harbin, Peoples R China

[2] Tumor Hosp Shanxi Prov, Comprehens Special Needs Dept, Taiyuan, Peoples R China

[3] First Hosp Harbin City, Dept Oncol, Harbin, Peoples R China

来源：

TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2016年 / 15卷 / 03期

关键词：

nimotuzumab; epidermal growth factor receptor; radiation; chemoradiation; gemcitabine; cell cycle; apoptosis; GROWTH-FACTOR-RECEPTOR; CARCINOMA-CELLS; EGFR; ANTIBODY; RADIOTHERAPY; DOCETAXEL; SURVIVAL; ZD1839; LINES; HEAD;

D O I：

10.1177/1533034615585209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study was performed to observe the effect of the combination of nimotuzumab with radiation or gemcitabine-based chemoradiation on antipancreatic cancer cell therapy. Pancreatic cancer cells (PANC-1) were treated with nimotuzumab alone or combined with radiation (2, 4, or 8 Gy), which was either with or without gemcitabine chemotherapy. Cell proliferation, cell cycle distribution, and apoptosis were observed. The inhibition rate, the percentage of G2/M phase arrest, and the apoptosis rate of the combined nimotuzumab with radiation group was significantly higher than the group without nimotuzumab (P <.001). The inhibition rate, the percentage of G2/M phase, and the apoptosis rate of the nimotuzumab therapy combined with gemcitabine-based chemoradiation group were obviously higher than that in gemcitabine-based chemoradiation group (P <.001). In conclusion, nimotuzumab could enhance the anticancer effect of radiation and gemcitabine-based chemoradiation in PANC-1 cancer cells because of the enhancement of cell cycle arrest and apoptosis.

引用

页码：446 / 452

页数：7

共 23 条

[11] C225 antiepidermal growth factor receptor antibody enhances the efficacy of docetaxel chemoradiotherapy [J].

Nakata, E ;

Hunter, N ;

Mason, K ;

Fan, Z ;

Ang, KK ;

Milas, L .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (04) :1163-1173

[12] Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck [J].

Osorio Rodriguez, Marta ;

Cruz Rivero, Teresa ;

del Castillo Bahi, Ramon ;

Roca Muchuli, Carlos ;

Azcue Bilbao, Miguel ;

Neninger Vinageras, Elia ;

Alert, Jose ;

Jimenez Galainena, Julio ;

Rodriguez, Edmundo ;

Gracias, Elias ;

Mulen, Barbara ;

Wilkinson, Barbara ;

Lucia de Armas, Esther ;

Perez, Kirenia ;

Pineda, Idael ;

Frometa, Milagros ;

Leonard, Idrissa ;

Mullens, Vladimir ;

Viada, Carmen ;

Luaces, Patricia ;

Torres, Olga ;

Iznaga, Normando ;

Crombet, Tania .

CANCER BIOLOGY & THERAPY, 2010, 9 (05) :343-349

[13] Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin [J].

Ramakrishnan, Melarkode S. ;

Eswaraiah, Anand ;

Crombet, Tania ;

Piedra, Patricia ;

Saurez, Giselle ;

Iyer, Harish ;

Arvind, A. S. .

MABS, 2009, 1 (01) :41-48

[14]

Sarris EG, 2013, J PANCREAS, V14, P395, DOI 10.6092/1590-8577/1654

[15] Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response [J].

Tzeng, Ching-Wei D. ;

Frolov, Andrey ;

Frolova, Natalya ;

Jhala, Nirag C. ;

Howard, J. Harrison ;

Vickers, Selwyn M. ;

Buchsbaum, Donald J. ;

Heslin, Martin J. ;

Arnoletti, J. Pablo .

ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (07) :2150-2158

[16] The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness - Poor prognosis in patients with pancreatic ductal adenocarcinoma [J].

Ueda, S ;

Ogata, S ;

Tsuda, H ;

Kawarabayashi, N ;

Kimura, M ;

Sugiura, Y ;

Tamai, S ;

Matsubara, S ;

Hatsuse, K ;

Mochizuki, H .

PANCREAS, 2004, 29 (01) :E1-E8

[17] Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model [J].

Vallera, D. A. ;

Stish, B. J. ;

Shu, Y. ;

Chen, H. ;

Saluja, A. ;

Buchsbaum, D. J. ;

Vickers, S. M. .

GUT, 2008, 57 (05) :634-641

[18]

[汪洋 WANG Yang], 2009, [中国癌症杂志, China Oncology], V19, P856

[19] Chemical radiosensitizers for use in radiotherapy [J].

Wardman, P. .

CLINICAL ONCOLOGY, 2007, 19 (06) :397-417

[20]

Xianzhen W, 2011, PRACT ONCOL J, V25, P453, DOI [10.3969/j.issn.1002-3070.2011.05.012, DOI 10.3969/J.ISSN.1002-3070.2011.05.012]

← 1 2 3 →